p53 protein immunoreactivity in fibrohistiocytic tumors of the skin

Pathology

Volumn 30, Issue 3, 1998, Pages 272-275

  Lee, C S ^a,c   Chou, S T ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HEIDELBERG REPATRIATION HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Atypical fibroxanthoma; Dermatofibroma; Dermatofibrosarcoma; Immunohistochemistry; p53; Tumor suppressor gene

Indexed keywords

PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; FIBROXANTHOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; SKIN TUMOR;

EID: 0031660104     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313029800169436     Document Type: Article

References (31)

1. Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992; 140: 145-53.
2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
3. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature 1986; 319: 783-4.
4. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86: 8763-7.
5. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705-8.
6. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988; 41: 178-83.
7. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
8. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-21.
9. Lee CS, Rush M, Charalambous D, Rode J. Immunohistochemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterol Hepatol 1993; 8: 465-9.
10. Boag G, Lee CS, Charalambous D, Rode J. p53 expression in laryngeal carcinoma. Pathology 1993; 25: 394-7.
11. Fletcher CDM, Evans BJ, Macartney JC, Smith N, Wilson Jones E, McKee PH. Dermatofibrosarcoma protuberans: a clinicopathological and immunohistochemical study with a review of the literature. Histopathology 1985; 9: 921-38.
12. Heenan PJ. Tumors of the fibrous tissue involving the skin In: Elder D, Elenitsas R, Jaworsky C, Johnson Jr B, editors. Lever's histopathology of the skin. 8th ed. Philadelphia: Lippincott-Raven, 1997; 847-65.
13. Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer 1986; 57: 368-76.
14. Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
15. De Leo AB, Jay G, Appella E, Du Bois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979; 76(5): 2420-4.
16. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984; 312: 646-9.
17. Finlay C, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-9.
18. Reihsaus E, Kohler M, Kraiss S, Oren M, Montenarh M. Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 1990; 5: 137-45.
19. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8.
20. Holm R, Skomedal H, Heiland A, Kristensen G, Borresen AL, Nesland JM. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant and malignant tissues of the cervix uteri. J Pathol 1993; 169: 21-6.
21. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 64: 75-81.
22. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-9.
23. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991; 138: 807-13.
24. Li J, Yang G, Li G. Observations on tumor and metastatic suppressor gene status in human fibrous neoplasms with particular emphasis on p53 and nm23. Int J Surg Pathol 1996; 4: 87-92.
25. Nestle FO, Nickoloff BJ, Burg G. Dermatofibroma: an abortive immunoreactive process mediated by dermal dendritic cells. Dermatology 1995; 190: 265-8.
26. Diaz-Cascajo C, Bastida-Inarrea J, Borrego L, Carretero-Hernandez G. Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: lack of correlation with proliferation rate. J Cutan Pathol 1995; 22: 304-9.
27. Dei Tos AP, Maestro R, Doglioni C, Gasparotto D, Boiocchi M, Laurino L, Fletcher CDM. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol 1994; 145: 11-7.
28. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
29. Lee CS, Pirdas A, Lee MWK. p53 in cutaneous melanoma: immunoreactivity and correlation with prognosis. Austral J Dermatol 1995; 36: 192-5.
30. McGregor JM, Yu CCW, Dublin EA, Barnes DM, Levison DA, MacDonald DM. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993; 128: 606-11.
31. Sun XF, Carstensen J, Zhang H, Stal O, Wingren S, Hatschek T, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340: 1369-73.